The prognostic value of myosteatosis in pancreatic cancer: A systematic review and meta-analysis
- PMID: 39442392
- DOI: 10.1016/j.clnu.2024.10.017
The prognostic value of myosteatosis in pancreatic cancer: A systematic review and meta-analysis
Abstract
Background and aims: The phenomenon of myosteatosis, characterized by the accumulation of ectopic fat within and surrounding skeletal muscle, has been identified as a potential adverse factor in the prognosis of individuals with cancer. This systematic review and meta-analysis sought to examine the association between myosteatosis and survival rates as well as postoperative complications in patients diagnosed with pancreatic cancer (PC).
Methods: A systematic search was conducted on Web of Science, Embase, and Pubmed until March 25, 2024, to identify pertinent articles assessing the prognostic significance of myosteatosis in patients with PC, utilizing the search terms: myosteatosis, PC, and prognosis. The selected studies were utilized to investigate the prognostic impact of myosteatosis on the survival of PC patients. Forest plots and pooled effects models were employed to present the findings of this meta-analysis. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale (NOS). A total of 565 studies were initially identified from the three databases, with 14 retrospective cohort studies ultimately included in the final quantitative analysis.
Results: The meta-analysis revealed a significant association between myosteatosis and both overall survival (OS) [Hazard Ratio (HR): 1.55, 95 % Confidence Interval (CI): 1.40-1.72, P < 0.001, I2 = 0.0 %] and recurrence-free survival (RFS) (HR 1.48, 95 % CI: 1.17-1.86, P = 0.001, I2 = 0.0 %) in patients diagnosed with PC. Subgroup analyses revealed that myosteatosis continued to be a negative prognostic factor in PC across various treatment modalities, patient populations, and myosteatosis assessment methods. Additionally, myosteatosis was identified as a risk factor for postoperative complications, with a pooled odds ratio of 2.20 (95 % CI: 1.45-3.35, P < 0.001, I2 = 37.5 %). All included studies achieved NOS scores of 6 or higher, indicating a relatively high level of methodological quality.
Conclusion: These results suggest that myosteatosis is significantly associated with both survival outcomes and postoperative complications in patients with PC.
Keywords: Meta-analysis; Myosteatosis; Pancreatic cancer; Prognosis; Skeletal muscle density.
Copyright © 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Conflict of interest statement
Conflict of interest There is no conflict of interest.
Similar articles
-
Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis.Clin Exp Med. 2025 May 16;25(1):164. doi: 10.1007/s10238-025-01671-6. Clin Exp Med. 2025. PMID: 40377729 Free PMC article.
-
Myosteatosis reduces overall survival in patients with digestive system malignancies: a meta-analysis with trial sequential analysis.Nutr Res. 2021 Oct;94:25-33. doi: 10.1016/j.nutres.2021.08.003. Epub 2021 Aug 23. Nutr Res. 2021. PMID: 34583210
-
Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis.iScience. 2024 Nov 7;27(12):111343. doi: 10.1016/j.isci.2024.111343. eCollection 2024 Dec 20. iScience. 2024. PMID: 39640579 Free PMC article.
-
Myosteatosis and prognosis in cancer: Systematic review and meta-analysis.Crit Rev Oncol Hematol. 2020 Jan;145:102839. doi: 10.1016/j.critrevonc.2019.102839. Epub 2019 Dec 20. Crit Rev Oncol Hematol. 2020. PMID: 31877534
-
Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis.J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1270-1282. doi: 10.1002/jcsm.12575. Epub 2020 Jun 1. J Cachexia Sarcopenia Muscle. 2020. PMID: 32483936 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical